Freedom Meditech has launched the CLEARPATH DS-120TM, a new tool cleared by the FDA to non-invasively measure autofluorescence of the crystalline lens by scanning the eye with blue light. Studies show elevated autofluorescence levels are linked to advanced glycosylated end products associated with diabetes. The device generates fluorescence ratio measurements to potentially help predict risk for conditions like cataracts.